US Stock MarketDetailed Quotes
BCDA BioCardia
- 2.260
- +0.125+5.85%
Close Nov 22 16:00 ET
- 2.300
- +0.040+1.77%
Post 20:01 ET
10.36MMarket Cap-560P/E (TTM)
2.320High2.140Low30.70KVolume2.150Open2.135Pre Close69.62KTurnover0.83%Turnover RatioLossP/E (Static)4.58MShares10.79052wk High3.76P/B8.39MFloat Cap1.84052wk Low--Dividend TTM3.71MShs Float129.000Historical High--Div YieldTTM8.43%Amplitude1.840Historical Low2.267Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioCardia Stock Forum
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia has completed its Phase III CardiAMP HF trial, a randomized, double-blind, placebo-controlled study evaluating the CardiAMP Cell Therapy System for heart failure treatment. The trial enrolled 125 patients across 18 US hospitals, with 115 patients randomized 3:2 between treatment and control groups. The therapy, which received FDA Breakth...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
BioCardia (Nasdaq: BCDA), a leader in cardiovascular and pulmonary disease therapeutics, has announced the pricing of an upsized $7.2 million public offering. The offering includes 2,400,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 2,400,000 shares at $3.00 per share and accompanying warrant. The warrants have a 5-year expirati...
No comment yet